---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-24-000193"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:09:39.742277+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex Q2 product revenue $2.65B (+6% YoY); raises FY 2024 guidance to $10.65-10.85B

## Summary
- GAAP net loss of $3.6B in Q2 due to $4.4B AIPR&D charge from Alpine acquisition.
- Non-GAAP net loss of $3.3B; combined R&D and SG&A expenses increased to $1.3B.
- FDA accepted NDAs for vanzacaftor triple (PDUFA Jan 2, 2025) and suzetrigine (PDUFA Jan 30, 2025).
- CASGEVY launches ongoing; >35 ATCs activated; early access program in France for SCD.
- Year-end cash $10.2B vs $13.7B end of 2023; cash used for Alpine acquisition.

## SEC filing metadata
- accession: 0000875320-24-000193
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532024000193/0000875320-24-000193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532024000193/vrtx-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-24-000193
- JSON: https://secwatch.observer/filing/0000875320-24-000193.json
- Plain text: https://secwatch.observer/filing/0000875320-24-000193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.